Despite NIFTP’s extremely low-recurrence rate of 0.6% (two cases), there remains disagreement regarding NIFTP’s true malignant potential (74–80). Despite its likely benign and, at worst, indolent nature, current ATA guidelines recommend lobectomy as definitive therapy for NIFTP. More importantly, however, and, apropos of this review, Afirma® GEC and Thyroseq® V2 validation studies occurred before the establishment of NIFTP as a distinct entity. Because of this one needs to be circumspect about the real utility of these marker panels. And, as a consequence, these molecular diagnostic panels require recalibration to appropriately account for the newly introduced entity, NIFTP; a lesion that should likely not be considered malignant (70, 81, 82).